Omega-3 fatty acids vs corn oil, major adverse cardiovascular events in patients at high risk

What The Study Did: This randomized trial examines the effects on cardiovascular outcomes of a carboxylic acid formulation of EPA and DHA (omega-3 CA) with documented favorable effects on lipid and inflammatory markers in patients with atherogenic dyslipidemia and high cardiovascular risk. Authors: Steven E. Nissen, M.D.,of the Cleveland Clinic Heart and Vascular Institute in Cleveland,…

A novel monoclonal antibody therapy cuts LDL cholesterol by half in a high-risk patient population,

The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol–the so-called “bad” cholesterol–by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study sponsored by Regeneron, are being…